Food supplement based on polymethoxylated flavones, tocotrienols, microencapsulated vitamin K2 and vegan vitamin D3 from Lichen
Property:
One of the risk factors in modern nutrition is represented by the excess of saturated fats and simple sugars and the lack of fiber and antioxidants, which combined with the high level of systemic inflammation that can arise from incorrect lifestyles, can promote an accumulation of cholesterol at the endothelial level with oxidation of LDL and extraosseous calcium deposition, the first step in the formation of atherosclerotic plaques. A balanced diet and the use of specific supplements can help to correctly convey calcium into the bones, to keep plasma levels of cholesterol, triglycerides and systemic inflammatory levels under control, for the overall well-being of the cardiovascular system and bone tissue .
SytriDK2 contains the unique synergy of vitamin D3 (cholecalciferol) the active form of vitamin D and vitamin K2 (menaquinone-7), with tocotrienols and flavonoids from citrus nobilis with respectively antioxidant and anti-inflammatory action and control of plasma lipid levels. The synergy between vitamin D3 and K2 is extensive
proven: vitamin D3 promotes correct absorption of calcium and promotes the production of proteins that require vitamin K2 to function properly.
The action of SytriDK2 is both on the osteoarticular system and on the cardiovascular system. Vitamin D3 is responsible for absorbing calcium which, in lack of vitamin K2 and magnesium, tends to deposit causing coronary calcifications which are a prelude to atherosclerosis phenomena.
Vitamin K2 promotes the fixation of calcium in bones and teeth, reducing the risk of fractures, improving density and level of bone mineralization in conditions such as osteopenia or osteoporosis, which manifest themselves above all with aging in conjunction with hormonal variations characteristic for example of menopause and with metabolic alterations (metabolic syndrome, diabetes 2).
Ingredients:
-
Citrus nobilis dry extract tit. 40% polymethoxylated flavones (PMF)
-
Palm tocotrienols
-
Vitamin K2 VITAL ® DELTA (Menaquinone-7)
-
Vitamin D3 (cholecalciferol) vegan from lichen
-
Anti-caking agents: corn starch, gum arabic, calcium carbonate, silicon dioxide, magnesium stearate
-
DRcaps TM acid-fast vegetable capsules
Component Properties:
-
Polymethoxylated flavones and tocotrienols : promote the reduction of total cholesterol levels in the blood, reduction of LDL levels in the blood, reduction of triglyceride levels in the blood, reduction of the ratio between LDL/HDL.
-
Vitamin K2 VITAL ® microencapsulated with half-life of approximately 72 hours with high purity and bioavailability: the action of vitamin K2 is twofold: it prevents the calcium that circulates in the blood, and that we take in through food, from depositing in the arteries and soft tissues, favoring the action of the protein Gla associated with the matrix and osteocalcin, fundamental for bone mineralization and whose deficiency leads to situations of osteoporosis. In this way, bone calcification is promoted, while the risk of the formation of "plaques" in the arteries and tissue calcifications is reduced.
-
Vegan Vitamin D3 from Icelandic lichen (2,000 IU): essential for the metabolism of calcium and phosphorus, bone mineralization and the assimilation of vitamin A, its deficiency causes rickets, osteomalacia and osteoporosis. Vitamin D3 promotes muscle contraction and trophism, combats diabetes and metabolic syndrome, stimulates the immune system by decreasing the incidence of infections and some autoimmune diseases and is a cardiovascular protection factor
How to use:
1 capsule per day, to be taken with water.
Packaging:
30 capsules in blister
AVERAGE CONTENT OF CHARACTERIZING INGREDIENTS | PER DAILY DOSE (1 CAPSULE) |
Citrus nobilis extract. dry tit. 40% contribution in PMF |
286 mg 114.5 mg |
Tocotrienols | 12 mg |
Vitamin K2 (Menaquinone-7) | 100 mcg |
Vitamin D3 (cholecalciferol) | 50 mcg (2000 IU) |
Bibliography:
- Borradaile NM, Carrol KK; Kurowska EM. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperitin and naringenin. Lipids. 1999;34(6):591-598
- Kurowska EM, Manthey JA, Hasegawa S, Manners GD, Vanderberg TA. Cholesterol-lowering effects of citrus juices, flavonoids and limonoids. Paper presented at: International Conference and Exhibition on Nutraceuticals and Functional foods; September 13-17,2000; Houston, TX.
- Kullo IJ, Gau GT, Tajik Aj. Novel risk factors for atherosclerosis. Mayo CLin Proc. 2000; 75(4): 369-380.
- Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression or 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol Chem. 1993; 268(15): 11230-11238.
- Guthrie N, Kurowska EM. Anticancer and cholesterol-lowering activities of tocotrienols. In: Widman REC, ed. Handbook of Nutraceuticals and Functional Food. Boca Raton, FL: CRC Press; 2000:269-280.
- Quereshi AA, Bradlow BA, Brace L rt al.Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids 1995; 30(12):1171-1177.
- Schurgers LJ, Vermeer C.- Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis 2000;30:298-307.
- Abedin M, Tintut Y, Demer LL. ascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161-70
- Saito E, Wachi H, Sato F, Sugitani H, Seyama Y. Treatment with vitamin K2 combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells. J Atheroscler Thromb 2007; 14:317-24
- Joline WJ Beulens, Michiel L. Bots, Femke Atsma, Marie-Louise EL Bartelink et al. – “High dietary menaquinone intake is associated with reduced coronary calcification” – Apr. 2008
- Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, Hofman A, Witteman JC. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004;134(11):3100-5.
- Beulens et al: High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2008 Jul 19. 25. Beulens JW, Bots ML, Atsma F, Bartelink ML, Prokop M, Geleijnse JM, Witteman JC